Adjuvant chemotherapy for patients with soft tissue sarcoma

Area of Science:

• Oncology
• Medical Research

Background:

• Soft tissue sarcomas are malignant tumors affecting connective tissues.
• Early-stage sarcomas (Enneking's stage I and II) present treatment challenges.
• Chemotherapy's role in improving survival for these sarcomas requires further investigation.

Purpose of the Study:

• To evaluate the impact of chemotherapy on survival rates in patients with early-stage soft tissue sarcoma.
• To analyze the effect of chemotherapy on the development and progression of lung metastases.

Main Methods:

• Retrospective analysis of 40 patients with Enneking's stage I and II soft tissue sarcoma treated between 1965 and 1992.
• Comparison of survival rates between patients who received VACA chemotherapy (vincristine, actinomycin-D, cyclophosphamide, doxorubicin) and those who did not.
• Assessment of time to lung metastasis development and survival duration after metastasis.

Main Results:

• The 5-year survival rate was significantly higher in the chemotherapy group (56%) compared to the non-chemotherapy group (39%) (p < 0.02).
• For Stage II patients, chemotherapy improved the 5-year survival rate from 31% to 40% (p < 0.05).
• Chemotherapy significantly delayed lung metastasis development (21.2 vs. 9.4 months) and prolonged survival after metastasis (26 vs. 7.4 months).

Conclusions:

• The VACA chemotherapy regimen demonstrates a significant survival benefit for patients with early-stage soft tissue sarcoma.
• Chemotherapy effectively reduces the incidence of lung metastases and improves outcomes after their development.
• Adjuvant chemotherapy should be considered for managing early-stage soft tissue sarcomas to enhance patient survival.